Vivani Medical (VANI) 10-K 28 Mar 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 23, 2022	Jun. 30, 2021
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-36747
Entity Registrant Name	Second Sight Medical Products, Inc.
Entity Central Index Key	0001266806
Entity Tax Identification Number	02-0692322
Entity Incorporation, State or Country Code	CA
Entity Address, Address Line One	13170 Telfair Avenue,
Entity Address, City or Town	Sylmar
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91342
City Area Code	818
Local Phone Number	833-5000
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 145,500,000
Common stock outstanding		39,409,176
Documents Incorporated by Reference	Portions of the registrant’s Proxy Statement for the 2022 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Registrant intends to file a definitive proxy statement with the Securities and Exchange Commission within 120 days after the end of registrant’s fiscal year ended December 31, 2021.
Auditor Firm ID	207
Auditor name	Santa Monica
Auditor location	California
Warrant [Member]
Common stock outstanding		7,680,938
Common Stock [Member]
Title of 12(b) Security	Common Stock
Trading Symbol	EYES
Security Exchange Name	NASDAQ
Warrants [Member]
Title of 12(b) Security	Warrants
Trading Symbol	EYESW
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 69,593	$ 3,177
Prepaid expenses and other current assets	914	1,092
Total current assets	70,507	4,269
Property and equipment, net	117	174
Right-of-use asset	228
Deposits and other assets	27	17
Total assets	70,879	4,460
Current liabilities:
Accounts payable	519	486
Accrued expenses	548	1,210
Accrued compensation expense	748	173
Accrued clinical trial and grant expenses	462	1,063
Current operating lease liabilities	185
Current debt		2,200
Total current liabilities	2,462	5,132
Long term operating lease liabilities	52
Total liabilities	2,514	5,132
Stockholders’ equity (deficit):
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 300,000 shares authorized; shares issued and outstanding: 39,409 and 23,214 at December 31, 2021 and December 31, 2020, respectively	347,940	270,126
Additional paid-in capital	49,389	49,314
Accumulated other comprehensive loss	(379)	(448)
Accumulated deficit	(328,585)	(319,664)
Total stockholders’ equity (deficit)	68,365	(672)
Total liabilities and stockholders’ equity (deficit)	$ 70,879	$ 4,460

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, no par value (in dollars per share)	$ 0	$ 0
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares outstanding	0	0
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized	300,000	300,000
Common stock, shares issued	39,409	23,214
Common stock, shares outstanding	39,409	23,214

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net sales
Cost of sales	(130)	(500)
Gross profit	130	500
Operating expenses:
Research and development, net of grants	2,370	4,836
Clinical and regulatory, net of grants	378	1,687
Selling and marketing		701
General and administrative	6,315	5,943
Restructuring charges		2,229
Total operating expenses	9,063	15,396
Loss from operations	(8,933)	(14,896)
Interest income	12	16
Net loss	$ (8,921)	$ (14,880)
Net loss per common share – basic and diluted	$ (0.27)	$ (0.72)
Weighted average shares outstanding – basic and diluted	32,817	20,575

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Net loss	$ (1,283)	$ (2,501)	$ (2,294)	$ (2,843)	$ (1,291)	$ (1,603)	$ (3,100)	$ (8,886)	$ (8,921)	$ (14,880)
Other comprehensive income:
Foreign currency translation adjustments									69	114
Comprehensive loss									$ (8,852)	$ (14,766)

Consolidated Statements of Stoc

Consolidated Statements of Stockholder's Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 264,008	$ 48,613	$ (562)	$ (304,784)	$ 7,275
Balance ending (in shares) at Dec. 31, 2020	23,214				23,214
Balance beginning (in shares) at Dec. 31, 2019	15,643
Repurchase of fractional shares in connection with reverse stock split	$ (11)				$ (11)
Repurchase of fractional shares in connection with reverse stock split (in shares)	(2)
Issuance of common stock, net of issuance costs	$ 6,393	280			6,673
Issuance of common stock and warrants in connection with rights offering, net of issuance costs (in shares)	7,500
Issuance of common stock in connection with ATM	$ 6				6
Issuance of common stock in connection with ATM (in shares)	1
Stock-based compensation expense		421			421
Repurchase of ESPP shares as part of a rescission offer	$ (270)				(270)
Repurchase of ESPP shares as part of a rescission offer (in shares)	(39)
Cash-less exercise of underwriter’s warrants
Cash-less exercise of underwriters warrants (in shares)	96
Release of restricted stock units
Release of restricted stock units (in shares)	15
Comprehensive loss:
Net loss				(14,880)	(14,880)
Foreign currency translation adjustment			114		114
Comprehensive loss			114	(14,880)	(14,766)
Ending balance, value at Dec. 31, 2020	$ 270,126	49,314	(448)	(319,664)	$ (672)
Balance ending (in shares) at Dec. 31, 2021	39,409				39,409
Balance beginning (in shares) at Dec. 31, 2020	23,214				23,214
Issuance of common stock, net of issuance costs	$ 77,789				$ 77,789
Stock-based compensation expense		75			75
Exercise of underwriter’s warrants	$ 25				25
Exercise of underwriters warrants (in shares)	45
Comprehensive loss:
Net loss				(8,921)	(8,921)
Foreign currency translation adjustment			69		69
Comprehensive loss			69	(8,921)	(8,852)
Ending balance, value at Dec. 31, 2021	$ 347,940	$ 49,389	$ (379)	$ (328,585)	$ 68,365
Comprehensive loss:
Issuance of shares of common stock, net of issuance costs (in shares)	16,150
Stock Issued During Period, Shares, New Issues	16,150

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (8,921)	$ (14,880)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization of property and equipment	70	164
Stock-based compensation	75	421
Non-cash lease expense	9	3
Restructuring charges-inventory impairment		1,214
Changes in operating assets and liabilities:
Accounts receivable		461
Inventories		529
Prepaid expenses and other assets	168	(785)
Accounts payable	63	(1,051)
Accrued expenses	(625)	(731)
Accrued compensation expenses	574	(2,524)
Accrued clinical trial and grant expenses	(601)	357
Net cash used in operating activities	(9,188)	(16,822)
Cash flows from investing activities:
Purchases of property and equipment	(14)	(330)
Sale of assets held for sale		398
Net cash provided by (used) in investing activities	(14)	68
Cash flows from financing activities:
Net proceeds from sale of common stock	77,789	6,679
Repurchase of ESPP shares and fractional shares in connection with reverse stock split		(281)
Debt financing (repayment)	(2,200)	2,200
Proceeds from exercise of options, warrants and employee stock purchase plan options	25
Net cash provided by financing activities	75,616	8,598
Effect of exchange rate changes on cash and cash equivalents	2	6
Cash and cash equivalents:
Net Increase (decrease)	66,416	(8,150)
Balance at beginning of year	3,177	11,327
Balance at end of year	69,593	3,177
Supplemental disclosure of cash flow information;
Interest	135
Non-cash financing activities:
Fair value of warrants issued in connection with issuance of common stock		$ 280

Organization and Business Opera

Organization and Business Operations	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Second Sight Medical Products, Inc. (“Second Sight,” the “Company,” “we,” “us,” “our” or similar terms), was incorporated in the State of California in 2003. We develop, manufacture and market implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. We are a recognized global leader in neuromodulation devices for blindness and are committed to developing new technologies to treat the broadest population of sight-impaired individuals. In 2007, Second Sight formed Second Sight (Switzerland) Sàrl, initially to manage clinical trials for its products in Europe, and later to manage sales and marketing in Europe, the Middle East and Asia Pacific. As the laws of Switzerland require at least two corporate stockholders, Second Sight (Switzerland) Sàrl is 99.5 0.5 100 We are currently developing the Orion® Visual Cortical Prosthesis System (“Orion”), an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma. A feasibility study of the Orion device is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles (“UCLA”) and Baylor College of Medicine in Houston (“Baylor”). Our commercially approved product, the Argus® II retinal prosthesis system (“Argus II”), entered clinical trials in 2006, received CE Mark approval for marketing and sales in the European Union (“EU”) in 2011, and received approval by the United States Food and Drug Administration (“FDA”) for marketing and sales in the United States in 2013. We began selling the Argus II in Europe at the end of 2011, Saudi Arabia in 2012, the United States and Canada in 2014, Turkey in 2015, Iran, Taiwan, South Korea and Russia in 2017, and Singapore in 2018. Given the limited addressable market of Argus II, we have made the decision to maximize capital efficiency by ceasing the production and sales of our Argus commercial and clinical activities and increase our investment of resources with our Orion clinical and R&D programs. Liquidity and Capital Resources From inception, our operations have been funded primarily through the sales of our common stock as well as from research and clinical grants. Funding of our business since 2020 has been primarily provided by: ● On June 25, 2021, we closed an underwritten public offering of 11,500,000 5.00 53.3 million ● On March 23, 2021, we closed our private placement to seven institutional investors of 4,650,000 6.00 24.5 million ● On May 5, 2020, we closed our underwritten public offering of 7,500,000 1.00 6.7 million ● On December 8, 2020, we borrowed $ 1 million 1.2 two Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We estimate that currently available cash will provide sufficient funds to enable the Company to meet its planned obligations for at least twenty-four months. Our ability to continue as a going concern is dependent on our ability to develop profitable operations through implementation of our business initiatives and/or raise additional capital, however, there can be no assurances that we will be able to do so.

Summary of Significant Accounti

Summary of Significant Accounting	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Second Sight and Second Sight Switzerland. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. We base our estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments and stock-based compensation, and the realization of deferred tax assets. Actual results could differ from those estimates Reclassifications Certain items in prior period financial statements have been reclassified to conform to the presentation in the current period financial statements. Such reclassification did not impact our previously reported net loss on financial position. Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. Cash is carried at cost, which approximates fair value, and cash equivalents are carried at fair value. We generally invest funds that are in excess of current needs in high credit quality instruments such as money market funds. Property and Equipment Property and equipment are recorded at historical cost less accumulated depreciation and amortization. Improvements are capitalized, while expenditures for maintenance and repairs are charged to expense as incurred. Upon disposal of depreciable property, the appropriate property accounts are reduced by the related costs and accumulated depreciation. The resulting gains and losses are reflected in the consolidated statements of operations. Depreciation is provided for using the straight-line method in amounts sufficient to relate the cost of assets to operations over their estimated service lives. Leasehold improvements are amortized over the shorter of the life of the asset or the related lease term. Estimated useful lives of the principal classes of assets are as follows: Schedule of Estimated Useful Lives of Principal Classes of Assets Lab equipment 5 – 7 Computer hardware and software 3 – 7 Leasehold improvements 2 – 5 Furniture, fixtures and equipment 5 – 10 We review our property and equipment for impairment annually or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. As a result of our decision to cease marketing of Argus II we recorded an impairment of $ 0.7 million 0.4 million Depreciation and amortization of property and equipment amounted to $ 0.1 million 0.2 million Research and Development Research and development costs are charged to operations in the period incurred and amounted to $ 2.4 million 4.8 million Patent Costs Due to the uncertainty associated with the successful development of one or more commercially viable products based on our research efforts and any related patent applications, all patent costs, including patent-related legal, filing fees and other costs, including internally generated costs, are expensed as incurred. Patent costs were $ 0.4 million 0.2 million NIH Grant From time to time, we receive grants that help fund specific development programs. Any amounts received pursuant to grants are offset against the related operating expenses as the costs are incurred. During the years ended December 31, 2021 and 2020 grants offset against operating expenses were $ 1.4 million 1.3 million Concentration of Risk Credit Risk Financial instruments that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market funds with financial institutions that management deems credit worthy, and at times, cash balances may be in excess of FDIC and SIPC insurance limits of $ 250,000 500,000 250,000 We also maintain cash at a bank in Switzerland. Accounts at said bank are insured up to an amount specified by the deposit insurance agency of Switzerland. Foreign Operations The accompanying consolidated financial statements as of December 31, 2021 and 2020 include assets amounting to approximately $ 30,000 18,000 Fair Value of Financial Instruments The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. We determine the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, we perform an analysis of the assets and liabilities at each reporting period end. Cash equivalents, which include money market funds, are the only financial instrument measured and recorded at fair value in assets or liabilities on our consolidated balance sheet, and they are valued using Level 1 inputs. Stock-Based Compensation Pursuant to FASB ASC 718 Share-Based Payment (“ASC 718”), we record stock-based compensation expense for all stock-based awards. Under ASC 718, we estimate the fair value of stock options granted using the Black-Scholes option pricing model. The fair value for awards that are expected to vest is then amortized on a straight-line basis over the requisite service period of the award, which is generally the option vesting term. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option valuation model. The assumptions used in the Black-Scholes valuation model are as follows: ● The grant price of the issuances is determined based on the fair value of the shares at the date of grant. ● The risk free interest rate for periods within the contractual life of the option is based on the U.S. treasury yield in effect at the time of grant. ● We calculate the expected term of options using a weighted average of option vesting periods and an estimate of one-half of the period between vesting and expiration of the option. ● Volatility is determined based on our average historical volatilities since our trading history began in November 2014, supplemented with average historical volatilities of comparable companies in our similar industry. ● Expected dividend yield is based on current yield at the grant date or the average dividend yield over the historical period. We have never declared or paid dividends and have no plans to do so in the foreseeable future. Comprehensive Income or Loss We comply with provisions of FASB ASC 220, Comprehensive Income, which requires companies to report all changes in equity during a period, except those resulting from investment by owners and distributions to owners, for the period in which they are recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events from non-owner sources. Comprehensive and other comprehensive income (loss) is reported on the face of the financial statements. For the years ended December 31, 2021 and 2020 comprehensive income (loss) is the total of net income (loss) and other comprehensive income (loss) which, for us, consists entirely of foreign currency translation adjustments and there were no material reclassifications from other comprehensive loss to net loss during the years ended December 31, 2021 and 2020. Foreign Currency Translation and Transactions The financial statements and transactions of the subsidiary’s operations are reported in the local (functional) currency of Swiss francs (CHF) and translated into U.S. dollars in accordance with U.S. GAAP. Assets and liabilities of those operations are translated at exchange rates in effect at the balance sheet date. The resulting gains and losses from translating foreign currency financial statements are recorded as other comprehensive income (loss). Revenues and expenses are translated at the average exchange rate for the reporting period. Foreign currency transaction gains (losses) resulting from exchange rate fluctuations on transactions denominated in a currency other than the foreign operations’ functional currencies are included in expenses in the consolidated statements of operations. Income Taxes We account for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, we recognize deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. We record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. In the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of our recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should we determine that we would not be able to realize all or part of our deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. We have incurred losses for tax purposes since inception and have significant tax losses and tax credit carryforwards. As of December 31, 2021, we had federal and state of California income tax net operating loss carryforwards, which may be applied to future taxable income, of approximately $ 124.3 million 76.8 million 2035 2037 2033 2041 We experienced an “ownership change” within the meaning of Section 382(g) of the Internal Revenue Code of 1986, as amended, during the second quarter of 2017. The ownership change will subject our net operating loss carryforwards to an annual limitation, which will significantly restrict our ability to use them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the aggregate value of our stock at the time of the ownership change multiplied by a tax-exempt interest rate specified by the Internal Revenue Service. We have analyzed the available information to determine the amount of the annual limitation. Based on information available us, the 2017 limitation is estimated to range between be $1.4 million and $3.7 million annually. In total, we estimate that the 2017 ownership change will result in approximately $120 million and $56 million of federal and state net operating loss carryforwards expiring unused Product Warranties Our policy is to warrant all shipped products against defects in materials and workmanship for up to two years by replacing failed parts. We also provide a three-year 0.1 million 0.5 million Net Loss per Share Our computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common shareholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., convertible notes payable, convertible preferred stock, common stock warrants and stock options) as if they had been converted at the beginning of the periods presented, or the issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all common stock warrants and common stock options outstanding were anti-dilutive. Schedule of Net Loss Per Share At December 31, 2021, and 2020, we excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive (in thousands). 2021 2020 Underwriter’s warrants 10 77 Warrants issued with rights offerings 7,681 7,682 Common stock options 182 196 Total 7,873 7,955 Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology is shared between our Argus II and Orion branded systems. While we have ceased production and marketing the Argus II product indicated for individuals with retinitis pigmentosa, we are developing Orion as a next generation product with potential to treat a broader market of blind individuals, including the retinitis pigmentosa market. Restructuring Charge On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded further impairment charges to our inventory of $ 0.5 million 0.7 million 1.0 million Recently Adopted Accounting Standards We believe that any recently issued, but not yet effective, authoritative guidance, if currently adopted, would not have a material impact on our financial statement presentation or disclosures.

Money Market Funds

Money Market Funds	12 Months Ended
	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Money Market Funds	3. Money Market Funds Money market funds included in cash equivalents at December 31, 2021 were $69.5 million. Money market funds included in cash equivalents at December 31, 2020 totaled $3.1 million. The following table presents money market funds at their level within the fair value hierarchy at December 31, 2020 and 2019 (in thousands) Schedule of Money Market Funds at their Level within the Fair Value Hierarchy Total Level 1 Level 2 Level 3 December 31, 2021: Money market funds $ 69,487 $ 69,487 $ — $ — December 31, 2020: Money market funds $ 3,122 $ 3,122 $ — $ —

Selected Balance Sheet Detail

Selected Balance Sheet Detail	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Selected Balance Sheet Detail	4. Selected Balance Sheet Detail Property and equipment, net of accumulated depreciation and amortization Property and equipment consisted of the following at December 31, 2021 and 2020 (in thousands): Schedule of Property and Equipment 2021 2020 Laboratory equipment $ 584 $ 584 Computer hardware and software 82 69 666 653 Accumulated depreciation and amortization (549) (479) Property and equipment, net $ 117 $ 174 As a result of our decision to cease marketing of Argus II we recorded an impairment of $ 0.7 million 0.4 million Debt On December 8, 2020, we borrowed $ 1 million 1.2 million 12 Contract Liabilities Contract liabilities amounted to $ 335,000

Grants

Grants	12 Months Ended
	Dec. 31, 2021
Grants
Grants	5. Grants We received an award for $ 1.6 million 6.4 million five years 0.5 million 0.6 million 1.4 1.3

Warrants

Warrants	12 Months Ended
	Dec. 31, 2021
Warrants
Warrants	6. Warrants Underwriter’s Warrant Issued in Public Offering As a component of the funding underwriting fee of our May 5, 2020 public underwriting offer, we issued 375,000 1.25 May 5, 2025 10,125 67,125 297,750 44,482 95,434 Warrants Issued in Rights Offerings On February 22, 2019, we completed a registered rights offering to existing stockholders in which we sold approximately 5,976,000 5.792 11.76 five On March 6, 2017, we completed a registered rights offering to existing stockholders in which we sold approximately 1,706,000 11.76 11.76 A summary of warrant activity for the years ended December 31, 2021 and 2020 is presented below (in thousands, except per share and contractual life data) Summary of Warrant Activity Weighted Average Remaining Weighted Average Contractual Life Number of Shares Exercise Price (in Years) Warrants outstanding at December 31, 2019 7,682 11.76 Granted 375 1.25 Exercised (298 ) 1.25 Forfeited or expired — — Warrants outstanding at December 31, 2020 7,759 11.66 Granted — — Exercised (68 ) 1.25 Forfeited or expired — — Warrants outstanding at December 31, 2021 7,691 11.75 2.21 Warrants exercisable at December 31, 2021 7,691 11.75 2.21 Warrants exercisable at December 31, 2021 had $ 4,000

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2021
Retirement Benefits [Abstract]
Employee Benefit Plans	7. Employee Benefit Plans We have a 401(k) Savings Retirement Plan (the “Plan”) that covers substantially all full-time employees who meet the Plan’s eligibility requirements and provides for an employee elective contribution. The Plan provides for employer matching contributions. Employer contributions are discretionary and determined annually by the Board of Directors. For the years ended December 31, 2021 and 2020, employer contributions to the Plan totaled $ 0.1 million 0.1 million

Equity Securities

Equity Securities	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Equity Securities	8. Equity Securities On June 4, 2019, our shareholders approved an amendment to our articles of incorporation increasing our authorized no par value common shares from 200,000,000 300,000,000 Common Stock Issuable For the twelve months ended December 31, 2020 our non-employee members of our Board were compensated $ 0.1 million 0.1 million

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation Stock Options Under the 2003 Plan, as restated in June 2011, we were authorized to issue options covering up to 437,500 937,500 The 2011 Plan was further amended in 2015, 2016, 2017 and 2018 bringing the number of shares issuable under the Plan to 1,500,000 No option were granted under the 2011 Plan in 2021 and the plan expired at May 31, 2021. We recognized stock-based compensation cost of $ 0.1 0.4 The calculated value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions: Summary of Option Grant using the Black-Scholes Option-pricing Model 2020 Risk-free interest rate 0.31 1.50 Expected dividend yield 0 % Expected volatility 78.0 96.0 Expected term 6.02 Weighted-average grant date calculated fair value $ 3.72 A summary of stock option activity for the years ended December 31, 2021 and 2020 is presented below (in thousands, except per share and contractual life data): Summary of Stock Option Activity Weighted Weighted Average Number Average Remaining of Exercise Contractual Shares Price Life (in Years) Options outstanding at December 31, 2019 984 $ 21.75 Granted 228 5.49 Exercised — — Forfeited or expired (1,016 ) 19.34 Options outstanding at December 31, 2020 196 15.48 Granted — — Exercised — — Forfeited or expired (14 ) 12.95 Options outstanding, vested and expected to vest at December 31, 2021 182 $ 15.68 6.59 Options exercisable at December 31, 2021 148 $ 18.38 6.25 The exercise prices of common stock options outstanding and exercisable are as follows at December 31, 2021 (in thousands): Summary of Exercise Prices of Common Stock Options Outstanding and Exercisable Options Options Outstanding Exercisable Exercise Price (Shares) (Shares) $ 0.90 0.91 22 8 $ 5.67 6.64 85 64 $ 13.84 16.40 52 52 $ 32.80 40.00 10 10 $ 72.08 104.72 13 14 182 148 Stock options exercisable at December 31, 2021 had minimal intrinsic value. As of December 31, 2021, there was $ 0.1 million 2.03 Employee Stock Purchase Plan We adopted an employee stock purchase plan in June 2015 for all eligible employees. Under the plan, shares of our common stock may be purchased at six-month 85 stock (i) on the first trading day of the offering period or (ii) on the last trading day of the purchase period. An employee may purchase in any one calendar year shares of common stock having an aggregate fair market value of up to $ 25,000 12,500 241,719 45,468 2,470 39,467 270,000 We may continue to have potential liability even after this rescission offer is made due to our issuances of securities in possible violation of the federal and state securities laws. The Securities Act does not expressly provide that a rescission offer will terminate a purchaser’s right to rescind a sale of stock that was not registered or exempt from the registration requirements of the Securities Act. Should any offerees reject the rescission offer, we may continue to be potentially liable under the Securities Act for the purchase price or for certain losses if the shares have been sold. Restricted Stock Units The following table presented below summarizes Restricted Stock Unit (RSU) activity for the year ended December 31, 2020 (in thousands, except per share data): Summary of Restricted Stock Unit (RSU) Activity Weighted Average Grant Date Number Fair Value of Awards Per Share Outstanding as of December 31, 2019 61 $ 5.92 Awarded — Vested (15) 5.92 Forfeited/canceled (46) 5.92 Outstanding as of December 31, 2020 — There was no activity in the year ended December 31, 2021. As of December 31, 2021, there was no unrecognized compensation cost related to RSUs as they have all been canceled. The total stock-based compensation recognized for stock-based awards granted in the consolidated statements of operations for the years ended December 31, 2021 and 2020 is as follows (in thousands): Stock-based Compensation Expense 2021 2020 Research and development $ 22 $ 127 Clinical and regulatory 35 51 Selling and marketing — 41 General and administrative 18 202 Total $ 75 $ 421

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	10. Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets as of December 31, 2021 and 2020 are summarized below (in thousands): Schedule of Deferred Tax Assets 2021 2020 Stock-based compensation $ 401 $ 380 Research credits 8,629 8,848 Depreciation (52 ) (52 ) Net operating loss carryforwards 33,033 30,492 Inventory write down 81 82 Other 454 375 Total deferred tax assets 42,399 40,125 Valuation allowance (42,399) (40,125) Net deferred tax assets $ — $ — In assessing the potential realization of these deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon us attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2021 and 2020, management determined it was not more likely than not that our deferred tax assets will be realized, and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates. No 21 We experienced an “ownership change” within the meaning of Section 382(g) of the Internal Revenue Code of 1986, as amended, during the second quarter of 2017. The ownership change will subject our net operating loss carryforwards to an annual limitation, which will significantly restrict our ability to use them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the aggregate value of our stock at the time of the ownership change multiplied by a tax-exempt interest rate specified by the Internal Revenue Service. We analyzed the available information to determine the amount of the annual limitation. Based on information available to us, the 2017 limitation is estimated to range between $ 1.4 million 3.7 million 120 million 56 million As of December 31, 2021, after the ownership change under Section 382(g), we had federal and state income tax net operating loss carryforwards, which may be applied to future taxable income, of approximately $ 124.3 million expire. The state net operating loss carryforwards will expire at various dates from 2033 through 2041. We also have a federal and state research and development tax credit carryforwards totaling approximately $ 4,755,000 4,903,000 2023 through 2041 We file income tax returns in the U.S. federal jurisdiction and various states and are subject to income tax examinations by federal tax authorities for tax years ended 2017 and later and by state authorities for tax years ended 2016 and later. We currently are not under examination by any tax authority. Our policy is to record interest and penalties on uncertain tax positions as income tax expense. As of December 31, 2021, and 2020, we have no accrued interest or penalties related to uncertain tax positions. Second Sight Switzerland, our foreign subsidiary, has not had any taxable income in the prior and current years.

Product Warranties

Product Warranties	12 Months Ended
	Dec. 31, 2021
Guarantees and Product Warranties [Abstract]
Product Warranties	11. Product Warranties A summary of activity of our warranty liabilities, which are included in accrued expenses in the accompanying consolidated balance sheets, for the years ended December 31, 2021 and 2020 is presented below (in thousands): Schedule of Activity in the Company's Warranty Liabilities 2021 2020 Balance, beginning of year $ 200 $ 1,575 Additions — — Settlements — (875) Adjustments and other (150 ) (500 ) Total $ 50 $ 200 During 2021and 2020 we reduced our warranty expense by $ 0.1 million 0.5 million

Right-of-use Assets and Operati

Right-of-use Assets and Operating Lease Liabilities	12 Months Ended
	Dec. 31, 2021
Right-of-use Assets And Operating Lease Liabilities
Right-of-use Assets and Operating Lease Liabilities	12. Right-of-use Assets and Operating Lease Liabilities We lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease costs are recognized in the income statement over the lease term on a straight-line basis. Depreciation is computed using the straight-line method over the estimated useful life of the respective assets. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or restrictive covenants. As most of our leases do not provide an implicit rate, we used our estimated incremental borrowing rate of 10 June 18, 2020 210,730 150,000 0.9 million 2.3 million 2.4 million 150,000 On January 22, 2021, we entered into a lease agreement, effective February 1, 2021, to sub-lease office space to replace our existing headquarters. We pay $ 17,000 17,290 The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company’s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): Year ending December 31: 2022 $ 201 2023 52 Total lease payments 253 Less imputed interest (16) Total lease liabilities $ 237 Other supplemental information: Current operating lease liabilities $ 185 Long term operating lease liabilities 52 Total lease liabilities $ 237 Discount rate 10 % For the year ended December 31, 2021 For the year ended December 31, 2020 Cash paid for operating lease liabilities 170 303 Rent expense, including common area maintenance charges, was $ 179,000 303,000

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies License Agreements We have exclusive licensing agreements to utilize certain patents, related to the technology for visual prostheses. We have determined that only the agreement with Doheny Eye Institute (“DEI”) applies to Argus II and Orion requiring future royalty payments through 2033 0.5 In the past we have paid royalties under a license agreement with the Johns Hopkins University (“JHU”). The JHU agreement expired, along with the underlying patents, in 2018. Pursuant to these agreements, DEI and JHU, we have incurred costs of approximately $ 1,000 zero Indemnification Agreements We maintain indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. Clinical Trial Agreements Based upon FDA approval of Argus II, which was obtained in February 2013, we were required to collect follow-up data from subjects enrolled in our pre-approval trial for a period of up to ten years post-implant, which was extended through the year 2019. In addition, we conducted three post-market studies to comply with U.S. FDA, French, and European post-market surveillance regulations and requirements and are conducting an early feasibility clinical study of Orion. We have contracted with various universities, hospitals, and medical practices to provide these services. Payments are based on procedures performed for each subject and are charged to clinical and regulatory expense as incurred. Total amounts charged to expense for the years ended December 31, 2021 and 2020 were $ 0.4 million 1.1 million California Board Representation As of January 1, 2021, all publicly held domestic or foreign corporations whose principal executive offices are located in California must meet the minimum requirements for female directors and for directors from underrepresented communities on their boards as required respectively by Women on Boards (SB 826) and Underrepresented Communities on Boards (AB 979). California law authorizes the California Secretary of State to impose fines to enforce compliance of SB 826 including a $100,000 fine for "failure to timely file board member information with the Secretary of State"; a $100,000 fine for a first violation, defined as "each director seat required by this section to be held by a female, which is not held by a female during at least a portion of a calendar year"; and a $300,000 fine for subsequent violations. 100,000 Litigation, Claims and Assessments Three oppositions filed by Pixium Vision are pending in the European Patent Office, each challenging the validity of a European patent owned by us. The outcomes of the challenges are not certain, however, if successful, they may affect our ability to block competitors from utilizing our patented technology. We believe a successful challenge will not have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on our operations. As described in the Company’s 10-K for the year ended December 31, 2020, the Company had entered into a Memorandum of Understanding (“MOU”) for a proposed business combination with Pixium Vision SA (“Pixium”). In response to a press release by Pixium dated March 24, 2021, and subsequent communications between us and Pixium, our Board of Directors determined that the business combination with Pixium was not in the best interest of our shareholders. On April 1, 2021, we gave notice to Pixium that we were terminating the MOU between the parties and seeking an amicable resolution of termination amounts that may be due, however no assurance can be given that an amicable resolution will be reached. We accrued $ 1,000,000 Pixium indicated that it considered this termination wrongful, rejected the Company’s offers, but retained the $1,000,000 payment. On May 19, 2021, Pixium filed suit in the Paris Commercial Court, and currently claim damages of approximately €5.1 million or about $5.6 million. We believe we have fulfilled our obligations to Pixium with the liquidated damages payment of $1,000,000 and thus the Company does not believe any further loss accrual is necessary. In November 2020, we and Pixium retained Oppenheimer & Co. Inc. as placement agent for a proposed private placement of securities in connection with the Business Combination. On April 1, 2021, we received an invoice from Oppenheimer for more than $1.86 million. This amount includes a requested commission of 6.5% on $27.9 million raised in the private placement. We believe that claims for payment presented by this invoice are without merit. On or about July 19, 2021, Martin Sumichrast filed a complaint with the Superior Court of the State of California, County of Los Angeles—Central District, claiming that he is entitled to compensation for services, as well as exemplary and other damages in an amount to be determined at trial but not less than $2 million, which arise from his allegedly arranging and securing financing that the Company obtained in May 2020 via a registered underwritten public offering of common stock. The complaint was dismissed by the court on January 18, 2022. Sumichrast appealed the dismissal, however the appeal was subsequently abandoned on March 1, 2022. We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our financial statements, however the results of litigation and claims are inherently unpredictable. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

Quarterly Financial Summary (un

Quarterly Financial Summary (unaudited)	12 Months Ended
	Dec. 31, 2021
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Summary (unaudited)	13. Quarterly Financial Summary (unaudited) Schedule of Quarterly Financial Summary Three Months Ended December 31, September 30, June 30, March 31, (in thousands, except per share data) 2021 2021 2021 2021 Product sales $ — $ — $ — $ — Gross profit $ 130 $ — $ — $ — Operating loss $ (1,291 ) $ (2,503 ) $ (2,296 ) $ (2,843 ) Net loss $ (1,283 ) $ (2,501 ) $ (2,294 ) $ (2,843 ) Net loss per share – basic and diluted $ (0.03 ) $ (0.06 ) $ (0.08 ) $ (0.12 ) Three Months Ended December 31, September 30, June 30, March 31, 2020 2020 2020 2020 Product sales $ — $ — $ — $ — Gross profit $ 500 $ — $ — $ — Operating loss $ (1,274 ) $ (1,602 ) $ (3,116 ) $ (8,904 ) Net loss $ (1,291 ) $ (1,603 ) $ (3,100 ) $ (8,886 ) Net loss per share – basic and diluted $ (0.06 ) $ (0.07 ) $ (0.15 ) $ (0.57 )

Subsequent Event

Subsequent Event	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Event	14. Subsequent Event On February 4, 2022, we entered into an agreement and plan of merger with Nano Precision Medical, Inc., a California corporation (“NPM”), and, upon and subject to the execution of a joinder, NPM Acquisition Corp., a California corporation and a wholly-owned subsidiary of the Company (“Merger Sub”). Pursuant to the agreement and subject to the terms and conditions set forth therein, NPM will merge with and into Merger Sub (the “Merger”), and upon consummation of the merger, Merger Sub will cease to exist and NPM will become a wholly-owned subsidiary of the Company. Upon completion of the merger and subject to shareholder approval, the Company will change its name as agreed in the future and intends to change its trading symbol as NPM requests in writing following consultation with Nasdaq.

Summary of Significant Accoun_2

Summary of Significant Accounting (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Policies Principles of Consolidation	Policies Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Second Sight and Second Sight Switzerland. Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. We base our estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments and stock-based compensation, and the realization of deferred tax assets. Actual results could differ from those estimates
Reclassifications	Reclassifications Certain items in prior period financial statements have been reclassified to conform to the presentation in the current period financial statements. Such reclassification did not impact our previously reported net loss on financial position.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. Cash is carried at cost, which approximates fair value, and cash equivalents are carried at fair value. We generally invest funds that are in excess of current needs in high credit quality instruments such as money market funds.
Property and Equipment	Property and Equipment Property and equipment are recorded at historical cost less accumulated depreciation and amortization. Improvements are capitalized, while expenditures for maintenance and repairs are charged to expense as incurred. Upon disposal of depreciable property, the appropriate property accounts are reduced by the related costs and accumulated depreciation. The resulting gains and losses are reflected in the consolidated statements of operations. Depreciation is provided for using the straight-line method in amounts sufficient to relate the cost of assets to operations over their estimated service lives. Leasehold improvements are amortized over the shorter of the life of the asset or the related lease term. Estimated useful lives of the principal classes of assets are as follows: Schedule of Estimated Useful Lives of Principal Classes of Assets Lab equipment 5 – 7 Computer hardware and software 3 – 7 Leasehold improvements 2 – 5 Furniture, fixtures and equipment 5 – 10 We review our property and equipment for impairment annually or whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. As a result of our decision to cease marketing of Argus II we recorded an impairment of $ 0.7 million 0.4 million Depreciation and amortization of property and equipment amounted to $ 0.1 million 0.2 million
Research and Development	Research and Development Research and development costs are charged to operations in the period incurred and amounted to $ 2.4 million 4.8 million
Patent Costs	Patent Costs Due to the uncertainty associated with the successful development of one or more commercially viable products based on our research efforts and any related patent applications, all patent costs, including patent-related legal, filing fees and other costs, including internally generated costs, are expensed as incurred. Patent costs were $ 0.4 million 0.2 million
NIH Grant	NIH Grant From time to time, we receive grants that help fund specific development programs. Any amounts received pursuant to grants are offset against the related operating expenses as the costs are incurred. During the years ended December 31, 2021 and 2020 grants offset against operating expenses were $ 1.4 million 1.3 million
Concentration of Risk	Concentration of Risk Credit Risk Financial instruments that subject us to concentrations of credit risk consist primarily of cash and money market funds. We maintain cash and money market funds with financial institutions that management deems credit worthy, and at times, cash balances may be in excess of FDIC and SIPC insurance limits of $ 250,000 500,000 250,000 We also maintain cash at a bank in Switzerland. Accounts at said bank are insured up to an amount specified by the deposit insurance agency of Switzerland.
Foreign Operations	Foreign Operations The accompanying consolidated financial statements as of December 31, 2021 and 2020 include assets amounting to approximately $ 30,000 18,000
Fair Value of Financial Instruments	Fair Value of Financial Instruments The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. We determine the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, we perform an analysis of the assets and liabilities at each reporting period end. Cash equivalents, which include money market funds, are the only financial instrument measured and recorded at fair value in assets or liabilities on our consolidated balance sheet, and they are valued using Level 1 inputs.
Stock-Based Compensation	Stock-Based Compensation Pursuant to FASB ASC 718 Share-Based Payment (“ASC 718”), we record stock-based compensation expense for all stock-based awards. Under ASC 718, we estimate the fair value of stock options granted using the Black-Scholes option pricing model. The fair value for awards that are expected to vest is then amortized on a straight-line basis over the requisite service period of the award, which is generally the option vesting term. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option valuation model. The assumptions used in the Black-Scholes valuation model are as follows: ● The grant price of the issuances is determined based on the fair value of the shares at the date of grant. ● The risk free interest rate for periods within the contractual life of the option is based on the U.S. treasury yield in effect at the time of grant. ● We calculate the expected term of options using a weighted average of option vesting periods and an estimate of one-half of the period between vesting and expiration of the option. ● Volatility is determined based on our average historical volatilities since our trading history began in November 2014, supplemented with average historical volatilities of comparable companies in our similar industry. ● Expected dividend yield is based on current yield at the grant date or the average dividend yield over the historical period. We have never declared or paid dividends and have no plans to do so in the foreseeable future.
Comprehensive Income or Loss	Comprehensive Income or Loss We comply with provisions of FASB ASC 220, Comprehensive Income, which requires companies to report all changes in equity during a period, except those resulting from investment by owners and distributions to owners, for the period in which they are recognized. Comprehensive income is defined as the change in equity during a period from transactions and other events from non-owner sources. Comprehensive and other comprehensive income (loss) is reported on the face of the financial statements. For the years ended December 31, 2021 and 2020 comprehensive income (loss) is the total of net income (loss) and other comprehensive income (loss) which, for us, consists entirely of foreign currency translation adjustments and there were no material reclassifications from other comprehensive loss to net loss during the years ended December 31, 2021 and 2020.
Foreign Currency Translation and Transactions	Foreign Currency Translation and Transactions The financial statements and transactions of the subsidiary’s operations are reported in the local (functional) currency of Swiss francs (CHF) and translated into U.S. dollars in accordance with U.S. GAAP. Assets and liabilities of those operations are translated at exchange rates in effect at the balance sheet date. The resulting gains and losses from translating foreign currency financial statements are recorded as other comprehensive income (loss). Revenues and expenses are translated at the average exchange rate for the reporting period. Foreign currency transaction gains (losses) resulting from exchange rate fluctuations on transactions denominated in a currency other than the foreign operations’ functional currencies are included in expenses in the consolidated statements of operations.
Income Taxes	Income Taxes We account for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, we recognize deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. We record a valuation allowance to reduce our deferred tax assets to the amount that is more likely than not to be realized. In the event we were to determine that we would be able to realize our deferred tax assets in the future in excess of our recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should we determine that we would not be able to realize all or part of our deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. We have incurred losses for tax purposes since inception and have significant tax losses and tax credit carryforwards. As of December 31, 2021, we had federal and state of California income tax net operating loss carryforwards, which may be applied to future taxable income, of approximately $ 124.3 million 76.8 million 2035 2037 2033 2041 We experienced an “ownership change” within the meaning of Section 382(g) of the Internal Revenue Code of 1986, as amended, during the second quarter of 2017. The ownership change will subject our net operating loss carryforwards to an annual limitation, which will significantly restrict our ability to use them to offset taxable income in periods following the ownership change. In general, the annual use limitation equals the aggregate value of our stock at the time of the ownership change multiplied by a tax-exempt interest rate specified by the Internal Revenue Service. We have analyzed the available information to determine the amount of the annual limitation. Based on information available us, the 2017 limitation is estimated to range between be $1.4 million and $3.7 million annually. In total, we estimate that the 2017 ownership change will result in approximately $120 million and $56 million of federal and state net operating loss carryforwards expiring unused
Product Warranties	Product Warranties Our policy is to warrant all shipped products against defects in materials and workmanship for up to two years by replacing failed parts. We also provide a three-year 0.1 million 0.5 million
Net Loss per Share	Net Loss per Share Our computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) available to common shareholders divided by the weighted average number of common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., convertible notes payable, convertible preferred stock, common stock warrants and stock options) as if they had been converted at the beginning of the periods presented, or the issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all common stock warrants and common stock options outstanding were anti-dilutive. Schedule of Net Loss Per Share At December 31, 2021, and 2020, we excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive (in thousands). 2021 2020 Underwriter’s warrants 10 77 Warrants issued with rights offerings 7,681 7,682 Common stock options 182 196 Total 7,873 7,955
Operating Segments	Operating Segments Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. Our chief operating decision-maker reviews financial information presented on a consolidated basis. Accordingly, we consider ourselves to be in a single reporting segment, specifically the discovery, development and commercialization of visual prosthetics for profoundly blind individuals. We historically managed our Argus II and Orion programs on a consolidated basis within this single operating segment and do not assess the performance of our product lines or geographic regions on other measures of income or expense, such as program expense, operating income or net income. Our underlying technology consists of hardware components (implanted and wearable) and software. A vast majority of this underlying technology is shared between our Argus II and Orion branded systems. While we have ceased production and marketing the Argus II product indicated for individuals with retinitis pigmentosa, we are developing Orion as a next generation product with potential to treat a broader market of blind individuals, including the retinitis pigmentosa market.
Restructuring Charge	Restructuring Charge On March 31, 2020, due to the COVID-19 pandemic and related inability to secure additional funding, we laid off the majority of our employees and reduced our operating expenses significantly to allow for our continuing business operations. Due to our focus on Orion and wind down of selling and marketing activities related to Argus II, we recorded further impairment charges to our inventory of $ 0.5 million 0.7 million 1.0 million
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards We believe that any recently issued, but not yet effective, authoritative guidance, if currently adopted, would not have a material impact on our financial statement presentation or disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Principal Classes of Assets	Schedule of Estimated Useful Lives of Principal Classes of Assets Lab equipment 5 – 7 Computer hardware and software 3 – 7 Leasehold improvements 2 – 5 Furniture, fixtures and equipment 5 – 10
Schedule of Net Loss Per Share	Schedule of Net Loss Per Share At December 31, 2021, and 2020, we excluded the outstanding securities summarized below, which entitle the holders thereof to ultimately acquire shares of common stock, from our calculation of earnings per share, as their effect would have been anti-dilutive (in thousands). 2021 2020 Underwriter’s warrants 10 77 Warrants issued with rights offerings 7,681 7,682 Common stock options 182 196 Total 7,873 7,955

Money Market Funds (Tables)

Money Market Funds (Tables)	12 Months Ended
	Dec. 31, 2021
Cash and Cash Equivalents [Abstract]
Schedule of Money Market Funds at their Level within the Fair Value Hierarchy	The following table presents money market funds at their level within the fair value hierarchy at December 31, 2020 and 2019 (in thousands) Schedule of Money Market Funds at their Level within the Fair Value Hierarchy Total Level 1 Level 2 Level 3 December 31, 2021: Money market funds $ 69,487 $ 69,487 $ — $ — December 31, 2020: Money market funds $ 3,122 $ 3,122 $ — $ —

Selected Balance Sheet Detail (

Selected Balance Sheet Detail (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following at December 31, 2021 and 2020 (in thousands): Schedule of Property and Equipment 2021 2020 Laboratory equipment $ 584 $ 584 Computer hardware and software 82 69 666 653 Accumulated depreciation and amortization (549) (479) Property and equipment, net $ 117 $ 174

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Warrants
Summary of Warrant Activity	A summary of warrant activity for the years ended December 31, 2021 and 2020 is presented below (in thousands, except per share and contractual life data) Summary of Warrant Activity Weighted Average Remaining Weighted Average Contractual Life Number of Shares Exercise Price (in Years) Warrants outstanding at December 31, 2019 7,682 11.76 Granted 375 1.25 Exercised (298 ) 1.25 Forfeited or expired — — Warrants outstanding at December 31, 2020 7,759 11.66 Granted — — Exercised (68 ) 1.25 Forfeited or expired — — Warrants outstanding at December 31, 2021 7,691 11.75 2.21 Warrants exercisable at December 31, 2021 7,691 11.75 2.21 Warrants exercisable at December 31, 2021 had $ 4,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2021
Share-based Payment Arrangement [Abstract]
Summary of Option Grant using the Black-Scholes Option-pricing Model	We recognized stock-based compensation cost of $ 0.1 0.4 The calculated value of each option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions: Summary of Option Grant using the Black-Scholes Option-pricing Model 2020 Risk-free interest rate 0.31 1.50 Expected dividend yield 0 % Expected volatility 78.0 96.0 Expected term 6.02 Weighted-average grant date calculated fair value $ 3.72
Summary of Stock Option Activity	A summary of stock option activity for the years ended December 31, 2021 and 2020 is presented below (in thousands, except per share and contractual life data): Summary of Stock Option Activity Weighted Weighted Average Number Average Remaining of Exercise Contractual Shares Price Life (in Years) Options outstanding at December 31, 2019 984 $ 21.75 Granted 228 5.49 Exercised — — Forfeited or expired (1,016 ) 19.34 Options outstanding at December 31, 2020 196 15.48 Granted — — Exercised — — Forfeited or expired (14 ) 12.95 Options outstanding, vested and expected to vest at December 31, 2021 182 $ 15.68 6.59 Options exercisable at December 31, 2021 148 $ 18.38 6.25
Summary of Exercise Prices of Common Stock Options Outstanding and Exercisable	The exercise prices of common stock options outstanding and exercisable are as follows at December 31, 2021 (in thousands): Summary of Exercise Prices of Common Stock Options Outstanding and Exercisable Options Options Outstanding Exercisable Exercise Price (Shares) (Shares) $ 0.90 0.91 22 8 $ 5.67 6.64 85 64 $ 13.84 16.40 52 52 $ 32.80 40.00 10 10 $ 72.08 104.72 13 14 182 148
Stock-based Compensation Expense	The following table presented below summarizes Restricted Stock Unit (RSU) activity for the year ended December 31, 2020 (in thousands, except per share data): Summary of Restricted Stock Unit (RSU) Activity Weighted Average Grant Date Number Fair Value of Awards Per Share Outstanding as of December 31, 2019 61 $ 5.92 Awarded — Vested (15) 5.92 Forfeited/canceled (46) 5.92 Outstanding as of December 31, 2020 — There was no activity in the year ended December 31, 2021. As of December 31, 2021, there was no unrecognized compensation cost related to RSUs as they have all been canceled. The total stock-based compensation recognized for stock-based awards granted in the consolidated statements of operations for the years ended December 31, 2021 and 2020 is as follows (in thousands): Stock-based Compensation Expense 2021 2020 Research and development $ 22 $ 127 Clinical and regulatory 35 51 Selling and marketing — 41 General and administrative 18 202 Total $ 75 $ 421
Stock-based Compensation Expense	The total stock-based compensation recognized for stock-based awards granted in the consolidated statements of operations for the years ended December 31, 2021 and 2020 is as follows (in thousands): Stock-based Compensation Expense 2021 2020 Research and development $ 22 $ 127 Clinical and regulatory 35 51 Selling and marketing — 41 General and administrative 18 202 Total $ 75 $ 421

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets as of December 31, 2021 and 2020 are summarized below (in thousands): Schedule of Deferred Tax Assets 2021 2020 Stock-based compensation $ 401 $ 380 Research credits 8,629 8,848 Depreciation (52 ) (52 ) Net operating loss carryforwards 33,033 30,492 Inventory write down 81 82 Other 454 375 Total deferred tax assets 42,399 40,125 Valuation allowance (42,399) (40,125) Net deferred tax assets $ — $ —

Product Warranties (Tables)

Product Warranties (Tables)	12 Months Ended
	Dec. 31, 2021
Guarantees and Product Warranties [Abstract]
Schedule of Activity in the Company's Warranty Liabilities	A summary of activity of our warranty liabilities, which are included in accrued expenses in the accompanying consolidated balance sheets, for the years ended December 31, 2021 and 2020 is presented below (in thousands): Schedule of Activity in the Company's Warranty Liabilities 2021 2020 Balance, beginning of year $ 200 $ 1,575 Additions — — Settlements — (875) Adjustments and other (150 ) (500 ) Total $ 50 $ 200

Right-of-use Assets and Opera_2

Right-of-use Assets and Operating Lease Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Right-of-use Assets And Operating Lease Liabilities
The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company’s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate):	The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company’s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): Year ending December 31: 2022 $ 201 2023 52 Total lease payments 253 Less imputed interest (16) Total lease liabilities $ 237 Other supplemental information: Current operating lease liabilities $ 185 Long term operating lease liabilities 52 Total lease liabilities $ 237 Discount rate 10 % For the year ended December 31, 2021 For the year ended December 31, 2020 Cash paid for operating lease liabilities 170 303

Quarterly Financial Summary (_2

Quarterly Financial Summary (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2021
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Summary	Schedule of Quarterly Financial Summary Three Months Ended December 31, September 30, June 30, March 31, (in thousands, except per share data) 2021 2021 2021 2021 Product sales $ — $ — $ — $ — Gross profit $ 130 $ — $ — $ — Operating loss $ (1,291 ) $ (2,503 ) $ (2,296 ) $ (2,843 ) Net loss $ (1,283 ) $ (2,501 ) $ (2,294 ) $ (2,843 ) Net loss per share – basic and diluted $ (0.03 ) $ (0.06 ) $ (0.08 ) $ (0.12 ) Three Months Ended December 31, September 30, June 30, March 31, 2020 2020 2020 2020 Product sales $ — $ — $ — $ — Gross profit $ 500 $ — $ — $ — Operating loss $ (1,274 ) $ (1,602 ) $ (3,116 ) $ (8,904 ) Net loss $ (1,291 ) $ (1,603 ) $ (3,100 ) $ (8,886 ) Net loss per share – basic and diluted $ (0.06 ) $ (0.07 ) $ (0.15 ) $ (0.57 )

Organization and Business Ope_2

Organization and Business Operations (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jun. 25, 2021	Mar. 23, 2021	May 05, 2020	Dec. 31, 2021	Dec. 08, 2020	Dec. 31, 2007
Chairman of Board of Directors [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Other borrowings					$ 1,000
Unaffiliated Shareholders [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Other borrowings					$ 1,200
Common Stock [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Number of shares issued upon right offering	11,500,000	4,650,000	7,500,000
Share price (in dollars per share)	$ 5	$ 6	$ 1
Proceeds from issuance or sale of equity, total	$ 53,300,000	$ 24,500,000	$ 6,700,000
Second Sight Switzerland Sarl [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Share price (in dollars per share)				100.00%		99.50%
Second Sight Switzerland Sarl [Member] | Executive Officer [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Noncontrolling interest, ownership percentage by noncontrolling owners						0.50%

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Principal Classes of Assets (Details)	12 Months Ended
	Dec. 31, 2021
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Computer Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Computer Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	2 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years

Schedule of Net Loss Per Share

Schedule of Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Calculation of earnings per share common stock anti-dilutive securities	7,873	7,955
Underwriter Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Calculation of earnings per share common stock anti-dilutive securities	10	77
Warrants Issued With2017 Rights Offering [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Calculation of earnings per share common stock anti-dilutive securities	7,681	7,682
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Calculation of earnings per share common stock anti-dilutive securities	182	196

Summary of Significant Accoun_4

Summary of Significant Accounting (Details Narrative) - USD ($)	Jul. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Asset impairment charges		$ 700,000
Net proceeds on sale of Property Plant Equipment	$ 400,000
Depreciation and amortization of property and equipment		100,000	$ 200,000
Research and development costs		2,400,000	4,800,000
Patent costs		400,000	200,000
grants offset against operating expenses		1,400,000	1,300,000
FDIC insured amount		250,000
SPIC insured amount		500,000
SPIC cash limit coverage		250,000
Assets		70,879,000	4,460,000
Net operating losses carryforward		$ 124,300,000
Net operating loss carryforwards limitations		We have analyzed the available information to determine the amount of the annual limitation. Based on information available us, the 2017 limitation is estimated to range between be $1.4 million and $3.7 million annually. In total, we estimate that the 2017 ownership change will result in approximately $120 million and $56 million of federal and state net operating loss carryforwards expiring unused
Manufacture warranty period		3 years
Decrease in Warranty expenses		$ 100,000	500,000
Decrease in Warranty expenses		100,000	500,000
Severance payments			1,000,000
Argus I I Product [Member]
Property, Plant and Equipment [Line Items]
Asset impairment charges		700,000
Decrease in Warranty expenses		500,000
Other assets impairment charge		700,000
State and Local Jurisdiction [Member]
Property, Plant and Equipment [Line Items]
Net operating losses carryforward		4,903,000	76,800,000
State and Local Jurisdiction [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Operating loss carryforwards expiration year				2033
State and Local Jurisdiction [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Operating loss carryforwards expiration year				2041
Domestic Tax Authority [Member]
Property, Plant and Equipment [Line Items]
Net operating losses carryforward		124,300,000
Domestic Tax Authority [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Operating loss carryforwards expiration year				2035
Domestic Tax Authority [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Operating loss carryforwards expiration year				2037
Country [Member]
Property, Plant and Equipment [Line Items]
Assets		$ 30,000	$ 18,000

Schedule of Money Market Funds

Schedule of Money Market Funds at their Level within the Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Impairment Effects on Earnings Per Share [Line Items]
Money market funds	$ 69,487	$ 3,122
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member]
Impairment Effects on Earnings Per Share [Line Items]
Money market funds	69,487	3,122
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Impairment Effects on Earnings Per Share [Line Items]
Money market funds
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Impairment Effects on Earnings Per Share [Line Items]
Money market funds

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 666	$ 653
Accumulated depreciation and amortization	(549)	(479)
Property and equipment, net	117	174
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	584	584
Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 82	$ 69

Selected Balance Sheet Detail_2

Selected Balance Sheet Detail (Details Narrative) - USD ($)	Dec. 08, 2020	Jul. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Impairment charge			$ 700,000
Contract liabilities			335,000	$ 335,000
Unsecured Promissory Note Payable on31st December2021 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Interest rate on unsecured Promissory Note	12.00%
Unsecured Promissory Note Payable on31st December2021 [Member] | Chairman of Board of Directors [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other borrowings	$ 1,000,000
Unsecured Promissory Note Payable on31st December2021 [Member] | Unaffiliated Shareholders [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other borrowings	$ 1,200,000
Fixed Assets [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Impairment charge		$ 400,000
Argus I I Product [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Impairment charge			$ 700,000

Grants (Details Narrative)

Grants (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018
Grants
Received grant			$ 1,600,000
Grant receivable with intent to fund early feasibility clinical trial for five years			$ 6,400,000
Grant received funding period			5 years
Received grant	$ 500,000	$ 600,000
Grants against operating expenses	$ 1,400,000	$ 1,300,000

Summary of Warrant Activity (De

Summary of Warrant Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Exercised	67,125	297,750
Outstanding at ending	10,125
Warrant [Member]
Class of Warrant or Right [Line Items]
Outstanding at beginning	7,759	7,682
Outstanding at beginning	$ 11.66	$ 11.76
Granted		375
Granted	$ 0	$ 1.25
Exercised	(68)	(298)
Exercised	$ 1.25	$ 1.25
Forfeited or expired	0
Outstanding at ending	7,691	7,759
Outstanding at ending	$ 11.75	$ 11.66
Outstanding at ending	2 years 2 months 16 days
Exercisable at ending	7,691
Exercisable at ending	$ 11.75
Exercisable at ending	2 years 2 months 16 days

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	May 05, 2020	Feb. 22, 2019	Mar. 06, 2017	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Subsidiary, Sale of Stock [Line Items]
Number of warrant outstanding	375,000			10,125
Warrants exercise price (in dollars per share)	$ 1.25
Warrants expiration date	May 5, 2025
Warrants exercised				67,125	297,750
Issuance of common stock shares				44,482	95,434
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Number of warrant outstanding				7,691	7,759	7,682
Warrants exercise price (in dollars per share)				$ 11.75	$ 11.66	$ 11.76
Warrants exercised				(68)	(298)
Warrants exercisable, intrinsic value				$ 4,000
Right Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price (in dollars per share)		$ 11.76
Number of shares issued upon right offering		5,976,000	1,706,000
Share price (in dollars per share)		$ 5.792	$ 11.76
Additional share price (in dollars per share)		$ 11.76	$ 11.76
Term of warrants		5 years

Employee Benefit Plans (Details

Employee Benefit Plans (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Employer contributions to plan	$ 100,000	$ 100,000

Equity Securities (Details Narr

Equity Securities (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Jun. 04, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized (in shares)	300,000	300,000
Stock-based compensation expense	$ 75,000	$ 421,000
Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Board of director cash compensation		100,000
Stock-based compensation expense		100,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized (in shares)	200,000,000		300,000,000
Stock-based compensation expense

Summary of Option Grant using t

Summary of Option Grant using the Black-Scholes Option-pricing Model (Details)	12 Months Ended
	Dec. 31, 2020$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%
Expected term	6 years 7 days
Weighted-average grant date calculated fair value	$ 3.72
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.31%
Expected volatility	78.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.50%
Expected volatility	96.00%

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable, number of shares (in shares)	148
Share-based Payment Arrangement, Option [Member] | The2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding, number of shares (in shares)	196,000	984,000
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.48	$ 21.75
Granted		228,000
Granted, weighted average exercise price (in dollars per share)		$ 5.49
Forfeited or expired, number of shares (in shares)	(14,000)	(1,016,000)
Forfeited or expired, weighted average exercise price (in dollars per share)	$ 12.95	$ 19.34
Options vested and exected, number of shares (in shares)	182,000	196,000
Options vested and expected, weighted average exercise price (in dollars per share)	$ 15.68	$ 15.48
Options vested and expected, weighted average remaining contractual life (Year)	6 years 7 months 2 days
Options exercisable, number of shares (in shares)	148,000
Options exercisable, weighted average exercise price (in dollars per share)	$ 18.38
Options exercisable, weighted average remaining contractual life (Year)	6 years 2 months 30 days

Summary of Exercise Prices of C

Summary of Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) - shares	Dec. 31, 2021	Dec. 21, 2021
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (in shares)		182
Options Exercisable (in shares)	148
Exercise Price Range One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (in shares)		22
Options Exercisable (in shares)	8
Exercise Price Range One [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	0.90
Exercise Price Range One [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	0.91
Exercise Price Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (in shares)		85
Options Exercisable (in shares)	64
Exercise Price Range Two [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	5.67
Exercise Price Range Two [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	6.64
Exercise Price Range Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (in shares)		52
Options Exercisable (in shares)		52
Exercise Price Range Three [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	13.84
Exercise Price Range Three [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	16.40
Exercise Price Range Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (in shares)		10
Options Exercisable (in shares)	10
Exercise Price Range Four [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	32.80
Exercise Price Range Four [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	40
Exercise Price Range Five [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (in shares)		13
Options Exercisable (in shares)	14
Exercise Price Range Five [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	72.08
Exercise Price Range Five [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	104.72

Stock-based Compensation Expens

Stock-based Compensation Expense (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Outstanding, number of awards (in shares)		61
Outstanding, weighted average grant date fair value per share (in dollars per share)		$ 5.92
Awarded, number of awards (in shares)
Vested (in shares)		(15)
Vested, weighted average grant date fair value per share (in dollars per share)		$ 5.92
Forfeited/canceled, number of awards (in shares)		(46)
Forfeited/canceled, weighted average grant date fair value per share (in dollars per share)		$ 5.92
Forfeited/canceled, number of awards (in shares)
Allocated share-based compensation expense	$ 75	$ 421
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense	22	127
Clinical and Regulatory [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense	35	51
Selling and Marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense		41
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Allocated share-based compensation expense	$ 18	$ 202

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares options granted	1,500,000
The2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	437,500
Number of shares options granted	937,500
Share based Payment arrangement, nonvested	$ 100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 10 months 3 days
The2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock purchases interval period	6 months
Percentage of fair market value of Common stock	85.00%
Aggregate fair market value of common stock	$ 25,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee	12,500
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		241,719
Sale of shares cancelled for employees already purchased shares under plan	45,468
Share Based Compensation Arrangement by Share Based Payment Award Shares Resale by Employees	2,470
Repurchase and cancelation of common stock shares	39,467
Cost related to repurchase and cancelation of common stock shares	$ 270,000

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Stock-based compensation	$ 401	$ 380
Research credits	8,629	8,848
Depreciation	(52)	(52)
Net operating loss carryforwards	33,033	30,492
Inventory write down	81	82
Other	454	375
Total deferred tax assets	42,399	40,125
Valuation allowance	(42,399)	(40,125)
Net deferred tax assets

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2017
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Federal income tax provision	$ 0	$ 0
Effective federal statutory rate	21.00%
Net operating losses carryforward	$ 124,300,000
Research and development tax credit carryforwards expired	2023 through 2041
Domestic Tax Authority [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Net operating losses carryforward	$ 124,300,000
Research and development tax credit carryforwards	4,755,000
Domestic Tax Authority [Member] | Net Operating Loss Carryforwards Expiring Unused [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Net operating losses carryforward			$ 120,000,000
State and Local Jurisdiction [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Net operating losses carryforward	4,903,000	$ 76,800,000
State and Local Jurisdiction [Member] | Net Operating Loss Carryforwards Expiring Unused [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Net operating losses carryforward			$ 56,000,000
Minimum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Limitation arising from estimated ownership change	1,400,000
Maximum [Member]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]
Limitation arising from estimated ownership change	$ 3,700,000

Schedule of Activity in the Com

Schedule of Activity in the Company's Warranty Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Guarantees and Product Warranties [Abstract]
Balance, beginning of year	$ 200	$ 1,575
Additions
Settlements		(875)
Adjustments and other	(150)	(500)
Total	$ 50	$ 200

Product Warranties (Details Nar

Product Warranties (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Guarantees and Product Warranties [Abstract]
Decrease in warranty expenses	$ 100,000	$ 500,000

The Company evaluated the lease

The Company evaluated the lease amendment under the provisions of ASC 842. Information related to the Company’s right-of-use assets and related lease liabilities are as followings (in thousands, except for remaining lease term and discount rate): (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Right-of-use Assets And Operating Lease Liabilities
2022	$ 201
2023	52
Total lease payments	253
Less imputed interest	(16)
Total lease liabilities	237
Current operating lease liabilities	185
Long term operating lease liabilities	$ 52
Operating Lease, Weighted Average Discount Rate, Percent	10.00%
Cash paid for operating lease liabilities	$ 170	$ 303

Right-of-use Assets and Opera_3

Right-of-use Assets and Operating Lease Liabilities (Details Narrative)	12 Months Ended
	Dec. 31, 2021USD ($)ft²	Dec. 31, 2020USD ($)
Lessee, Lease, Description [Line Items]
Incremental borrowing rate	10.00%
Lease expiration date	Jun. 18, 2020
Other commitment	$ 9,000	$ 3,000
Operating Lease, Right-of-Use Asset	228,000
Liabilities Subject to Compromise, Early Contract Termination Fees	150,000
Rent paid	$ 17,000
Office space | ft²	17,290
Lease commitment	$ 179,000	$ 303,000
Lessor [Member]
Lessee, Lease, Description [Line Items]
Other commitment	210,730
Other Commitment	150,000
Utilities perating expense maintenance	900,000
Operating Lease, Right-of-Use Asset	2,300,000
Operating Lease, Liability	$ 2,400,000

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2021
Product Liability Contingency [Line Items]
License agreement term	through 2033
License royalty rate	0.50%
Agreements incurred cost	$ 130,000	$ 500,000
Clinical and regulatory expense	$ 400,000	1,100,000
Description of comunities	the California Secretary of State to impose fines to enforce compliance of SB 826 including a $100,000 fine for "failure to timely file board member information with the Secretary of State"; a $100,000 fine for a first violation, defined as "each director seat required by this section to be held by a female, which is not held by a female during at least a portion of a calendar year"; and a $300,000 fine for subsequent violations.
Accrued penalties and fines	$ 100,000
Liquidated damage			$ 1,000,000
Description of contract termination and claims	Pixium indicated that it considered this termination wrongful, rejected the Company’s offers, but retained the $1,000,000 payment. On May 19, 2021, Pixium filed suit in the Paris Commercial Court, and currently claim damages of approximately €5.1 million or about $5.6 million. We believe we have fulfilled our obligations to Pixium with the liquidated damages payment of $1,000,000 and thus the Company does not believe any further loss accrual is necessary.
License Fee [Member]
Product Liability Contingency [Line Items]
Agreements incurred cost	$ 0	$ 1,000

Schedule of Quarterly Financial

Schedule of Quarterly Financial Summary (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Product sales
Gross profit	130				500				130	500
Operating loss	(1,291)	(2,503)	(2,296)	(2,843)	(1,274)	(1,602)	(3,116)	(8,904)	(8,933)	(14,896)
Net loss	$ (1,283)	$ (2,501)	$ (2,294)	$ (2,843)	$ (1,291)	$ (1,603)	$ (3,100)	$ (8,886)	$ (8,921)	$ (14,880)
Earnings Per Share, Basic and Diluted	$ (0.03)	$ (0.06)	$ (0.08)	$ (0.12)	$ (0.06)	$ (0.07)	$ (0.15)	$ (0.57)	$ (0.27)	$ (0.72)